Harrow Health (NASDAQ:HROW) Shares Gap Down to $27.07

Shares of Harrow Health, Inc. (NASDAQ:HROW – Get Rating) gapped down prior to trading on Friday . The stock had previously closed at $27.07, but opened at $24.68. Harrow Health shares last traded at $22.78, with a volume of 410,707 shares changing hands.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Lake Street Capital lifted their price target on shares of Harrow Health from $24.00 to $37.00 and gave the company a “buy” rating in a research note on Monday, April 17th. LADENBURG THALM/SH SH increased their target price on shares of Harrow Health from $27.20 to $32.40 in a research note on Friday. B. Riley reiterated a “buy” rating on shares of Harrow Health in a research report on Thursday, May 4th. Finally, TheStreet raised shares of Harrow Health from a “d” rating to a “c” rating in a research note on Tuesday, April 11th.

Harrow Health Price Performance

The firm has a market cap of $663.89 million, a PE ratio of -42.38 and a beta of 0.18. The company has a quick ratio of 6.00, a current ratio of 6.35 and a debt-to-equity ratio of 3.82. The stock has a 50 day moving average price of $22.08 and a two-hundred day moving average price of $16.84.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Opaleye Management Inc. grew its stake in shares of Harrow Health by 12.9% in the 4th quarter. Opaleye Management Inc. now owns 3,775,000 shares of the company’s stock valued at $55,719,000 after purchasing an additional 431,183 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Harrow Health by 7.2% in the second quarter. Renaissance Technologies LLC now owns 1,167,812 shares of the company’s stock worth $8,502,000 after acquiring an additional 78,903 shares during the last quarter. Private Capital Management LLC increased its stake in Harrow Health by 1.2% in the fourth quarter. Private Capital Management LLC now owns 1,041,661 shares of the company’s stock valued at $15,375,000 after purchasing an additional 12,305 shares during the last quarter. Portolan Capital Management LLC acquired a new position in Harrow Health in the fourth quarter valued at $14,354,000. Finally, Assenagon Asset Management S.A. purchased a new stake in Harrow Health during the first quarter valued at about $16,980,000. Hedge funds and other institutional investors own 56.47% of the company’s stock.

Harrow Health Company Profile

(Get Rating)

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.